Navigation Links
Dr. Daniel Spyker, Former FDA acting Deputy Division Director of Cardiovascular, Respiratory, and Neurological Devices, Joins NDA Partners
Date:2/22/2017

NDA Partners Chairman Carl Peck, MD, announced today that Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in the FDA CDRH Division of Cardiovascular, Respiratory, and Neurological Devices and Medical Officer in CDER’s Pilot Drug Evaluation Staff has joined the company as an Expert Consultant.

In Dr. Spyker’s accomplished career, he held positions as Senior Director of Drug Safety and Pharmacovigilance at Alexza Pharmaceuticals; Director, Pharmacokinetics and Pharmacodynamic Sciences, Genentech, where he established the clinical pharmacology unit; and Senior Medical Director, Clinical Risk Assessment and Coordination Department at Purdue Pharma.

Dr. Spyker was a member of the Internal Medicine faculty in the Division of Clinical Pharmacology at the University of Virginia for 10 years, where he fostered and nurtured the Blue Ridge Poison Center. He was also founder and CEO of a software company specializing in poison center data collection and Bayesian pharmacokinetic applications.

“Dr. Daniel Spkyer’s knowledge and expertise of cardiovascular, respiratory, and neurological devices at FDA and in the Industry, in addition to his expertise in quantitative clinical pharmacology and toxicology, make him an excellent addition to NDA Partners. He will bring great value to our medical device clients and we are very pleased to welcome him,” said Dr. Feigal, who heads NDA Partners’ Medical Device Practice.

Dr. Spyker earned his PhD from the University of Minnesota in Electrical Engineering and Mathematics, his MD from the University of Virginia, and MS from Purdue University. He is board certified in Internal Medicine, a diplomate of the American Board of Medical Toxicology, and diplomate of the American Board of Clinical Pharmacology.

About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.

Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
MartinEarle(at)ndapartners(dot)com

Read the full story at http://www.prweb.com/releases/2017/02/prweb14083870.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Industry Leaders DuPont & Archer Daniels Midland Win Platts Global Energy Breakthrough Solution of the Year Award
2. Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director
3. Danielle Vitiello, MD of Fertility Centers of New England, Named Top Doc in Infertility Diagnosis and Treatment by NH Magazine
4. Global Regulatory Affairs Expert Daniela Drago, PhD Joins NDA Partners
5. Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board
6. XBiotech Adds Daniel Vasella to its Board of Directors
7. Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director
8. Dr. Daniel Von Hoff Joins Lixte Biotechnologys Scientific Advisory Board
9. GenoSpace Expands Its Management Team by Appointing Daniel Meyer as Chief Financial Officer
10. Repetitive Head Injuries May Not Cause Movement Problems for Former NFL Players
11. Dr. Deborah Wenkert Pediatrics Expert and Former Amgen Clinical Research Medical Director, Joins NDA Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2019)... , ... January 29, 2019 , ... ... (AskBio), today announced the dosing of the first patient in a phase 1/2 ... a serious disease associated with high morbidity and often leads to premature death. ...
(Date:1/30/2019)... WHITEHOUSE, N.J. (PRWEB) , ... January 30, 2019 ... ... brings together experts from pharma, academia and governmental agencies to discuss best practices ... Washington, DC from February 4-6. , At this year’s conference, Visikol will ...
(Date:1/28/2019)... SAN DIEGO (PRWEB) , ... January 28, 2019 ... ... proteins against libraries of low molecular weight compounds. In this early stage, false ... binding. At the same time, it is vital that screening techniques are highly ...
(Date:1/24/2019)... (PRWEB) , ... January 22, 2019 , ... ... since each trial has its own set of assumptions, and RFP creation and ... so evaluating bids is like comparing apples to oranges. These challenges can ultimately ...
Breaking Biology Technology:
(Date:2/12/2019)... SASKATOON, Canada (PRWEB) , ... February 12, 2019 ... ... immediately it will begin operating under its new name, KEYLEAF. The company ... more of its own plant-based extracts and ingredients as finished products under the ...
(Date:2/2/2019)... ... January 31, 2019 , ... ... , geared toward clinical operations executives and focusing on all facets of clinical ... effective project management, portfolio management, resource management, patient engagement, and more. , ...
(Date:1/25/2019)... ... January 24, 2019 , ... ... PhD, Assistant Professor of Microbiology at the Jackson Laboratory (JAX), to its Scientific ... world, Dr. Oh will bring to uBiome expertise in skin microbial interactions and ...
Breaking Biology News(10 mins):